We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnostic Test Kits for Dengue Virus Detection Evaluated

By LabMedica International staff writers
Posted on 28 Oct 2014
Laboratory diagnosis of dengue with a single serum specimen obtained during the acute phase of the illness requires tests to detect immunoglobulin M (IgM) antibodies to Dengue virus or the virus genome.

Commercially available diagnostic test kits for detection of the Dengue virus (DENV) non-structural protein 1 (NS1) and anti-DENV IgM have been evaluated for their sensitivity and specificity and other performance characteristics.

An international team of scientists led by those at the [US] Centers for Disease Control and Prevention (CDC; San Juan, Puerto Rico) examined newly available commercial tests that detect the virus protein NS1, as well as new tests for IgM anti-DENV in microplate or rapid diagnostic test (RDT) formats. This analytic study used specimens from laboratory confirmed dengue patients worldwide, which makes the results widely generalizable.

A DENV NS1 panel cconsisted of a total of 390 dengue patient serum specimens in three sub-panels: 192 dengue patients who were DENV positive by virus isolation and/or polymerase chain reaction (PCR) for DENV ribonucleic acid (RNA), 146 DENV RNA or culture negatives, and 52 challenge specimens from other illnesses or conditions. An anti-DENV IgM panel consisted of three subpanels with 527 patient serum specimens: 228 anti-DENV IgM positive paired specimens from patients with dengue and 155 DENV IgM negative and 144 challenge specimens. All specimens were tested by the solid-phase anti-DENV IgM Antibody Capture Enzyme Linked Immunosorbent Assay (IgM MAC-ELISA).

The DENV kits from seven different manufacturers were tested. The results were analyzed to determine sensitivity, specificity, inter-laboratory and inter-reader agreement, lot-to-lot variation and ease-of-use. NS1 ELISA sensitivity was 60% to 75% and specificity 71% to 80%; NS1 RDT sensitivity was 38% to 71% and specificity 76% to 80%; the IgM anti-DENV RDTs sensitivity was 30% to 96%, with a specificity of 86% to 92%, and IgM anti-DENV ELISA sensitivity was 96% to 98% and specificity 78% to 91%.

The authors concluded that NS1 tests were generally more sensitive in specimens from the acute phase of dengue and in primary DENV infection, whereas IgM anti-DENV tests were less sensitive in secondary DENV infections. The reproducibility of the NS1 RDTs ranged from 92% to 99% and the IgM anti-DENV RDTs from 88% to 94%.The study was published on October 16, 2014, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Centers for Disease Control and Prevention 



Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.